Lymphoma and Blood Disorders: Understanding New Treatment Options

Treatment options for lymphoma include chemotherapy, radiation, targeted medicines and immunotherapy. Newer approaches expand the choices for some patients; they do not replace every established treatment or offer the same benefit to every person.

The diagnosis, earlier treatments and the patient’s health shape which options a hematologist may consider. The examples below explain why specialist evaluation matters, rather than recommending a treatment.

[1]

CAR-T therapy uses T cells collected from a patient and modified in a laboratory to recognize a target on cancer cells. It is used for selected blood cancers, including certain lymphomas. Some patients experience lasting remissions, while others do not respond or later relapse.

Treatment requires specialist assessment, cell preparation and monitoring. Serious complications can include cytokine release syndrome and neurological effects. A remission should not be presented as a guaranteed cure.

[2]

Some antibody treatments bring T cells and cancer cells together, helping the immune cells attack the cancer. Unlike a personalized CAR-T product, these medicines do not require collection and modification of each patient’s own cells.

That difference does not mean treatment is immediately available or suitable for everyone. The treating team must assess the indication, risks, monitoring requirements and local access. Immune-related reactions and infections can be serious.

[3][4]

In November 2025, the US FDA approved epcoritamab with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. In the supporting randomized trial, the combination improved progression-free survival compared with lenalidomide and rituximab alone.

This is evidence for a specific regimen and study population, not a prediction of an individual patient’s outcome. The medicine carries warnings for cytokine release syndrome, neurological toxicity, infections and low blood-cell counts. US approval does not establish availability, eligibility or reimbursement in Israel.

[4]

Paroxysmal nocturnal hemoglobinuria (PNH) is a blood disorder involving complement-mediated damage to red blood cells, rather than a type of lymphoma. Complement inhibitors are one treatment approach.

For example, the FDA approved crovalimab for certain patients with PNH in 2024. Its schedule includes initial loading doses followed by maintenance injections every four weeks. Eligibility, infection precautions and ongoing monitoring require specialist oversight; the schedule is not a reason to assume it is the appropriate treatment for a particular patient.

[5]

For patients considering care across borders, the next step is an appropriate specialist review: confirm the diagnosis, understand previous treatment, and discuss which options are relevant and realistically accessible.

RKM INTL coordinates specialist and institutional access, document organization and communication. The treating physician and hospital retain responsibility for diagnosis, treatment recommendations, clinical acceptance and pricing.